GlaxoSmithKline's Votrient gets US panel nod for renal cancer
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's oral anti-angiogenic Votrient (pazopanib) won the overwhelming endorsement of the US FDA's oncologic drugs advisory panel for treating advanced renal cell carcinoma. The agency's experts voted 10 to zero that the anticancer agent had a favourable risk/benefit profile, despite the drug's hepatic risks.